The U.S. Supreme Court dismissed the final remaining appeal challenging President Donald Trump’s March travel ban.
A brief statement issued by the Supreme Court on Tuesday explained the case from Hawaii, which involved an earlier executive in March, no longer presents a “live case or controversy” because the provisions of the order have expired.
Trump replaced the expired March order with a new set of travel restrictions in September. The new order added restrictions on travel from Iran, Libya, Somalia, Syria, Yemen, Chad, Venezuela and North Korea.
In addition to dismissing the Hawaii case, the Supreme Court also vacated the decision under appeal, from the United States Court of Appeals for the 9th Circuit, in San Francisco, which can no longer be used as a precedent.
Justice Sonia Sotomayor dissented from the ruling to vacate the 9th Circuit’s decision, writing that she would’ve preferred it simply be dismissed to allow the appeals court decision to remain on record.
Landslides in western India kill five, while floods trap more
Sydney COVID-19 outbreak a ‘national emergency’ as cases spike
FBI says it got more than 4,500 tips on Kavanaugh, providing ‘relevant’ ones to Trump White House
Pelosi says ‘deadly serious’ Jan. 6 probe to go without GOP
Protests in Iran’s Khuzestan continue, spread to neighboring Lorestan
Entertainment7 days ago
Biz Markie, ‘Clown Prince of Hip-Hop’ known for ‘Just a Friend,’ dies at 57
Australia & NZ6 days ago
TikTok comedian who correctly guesses Covid numbers claims the NSW Health Department has told him to stop because he’s ‘compromising’ the system
North America7 days ago
Toronto Blue Jays announce return to Rogers Centre
Australia & NZ7 days ago
Sydney imposes more COVID-19 restrictions after lockdown fails to curb cases
North America6 days ago
Blue Jays set to host 15,000 fans in return to Toronto: Shapiro
Other6 days ago
Climate Change to Bring More Intense Storms Across Europe
food5 days ago
The best pizza city in the USA revealed
Health5 days ago
UAE reports 97 pct recovery in COVID-19 Sotrovimab clinical trial